Paeoniflorin increases the anti-tumor efficacy of sorafenib in tumor-bearing mice with liver cancer via suppressing the NF-κb/PD-l1 axis

Background: Sorafenib (Sor) represents a first-line therapy for hepatocellular carcinoma (HCC); however, its efficacy is constrained by secondary failure, which limits its clinical use. Recent studies have indicated that the suppression of Programmed cell death-Ligand 1 (PD-L1) may potentiate Sor's...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Junfei Li, Chenghui Zhu, Zengyu Zhang, Xiaorong Zheng, Chunlei Wang, Hongyan Zhang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2024-01-01
Colecção:	Heliyon
Assuntos:	Sorafenib Hepatocellular carcinoma NF-κB PD-L1 Paeoniflorin
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2405844024004924
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!